BioSpace News Archive

Findings from a study of 500 people with lupus published in Rheumatology and Therapy indicate a high level of burden with current treatments and unmet needs in managing lupus symptoms.

AB Science SA announced that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib.

Presidio Medical, Inc., a clinical-stage medical device company developing a transformational neuromodulation platform, today announced that Michael Onuscheck has been named the incoming Chief Executive Officer and Chairman of the Board.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis

Miromatrix Medical Inc. (Nasdaq: MIRO) (“Miromatrix”), a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives, today announced the closing of its initial public offering of 5,520,000 shares of common stock.

Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of MYCAPSSA

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Michael Doyle to the position of Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced the commencement of a proposed underwritten public offering of $150 million of shares of its common stock.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today commented on the recent decision by Health Canada to re-issue a Notice of Compliance (“NOC”) for Ruzurgi®